Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo

The clinical potential of PARP-1 inhibitors has been recognized > 10 years ago, prompting intensive research on their pharmacological application in several branches of medicine, particularly in oncology. However, natural or acquired resistance of tumors to known PARP-1 inhibitors poses a serious...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Colin, Ji, Yingbiao, Lodhi, Niraj, Kotova, Elena, Pinnola, Aaron Dan, Golovine, Konstantin, Makhov, Peter, Pechenkina, Kate, Kolenko, Vladimir, Tulin, Alexei V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264309/
https://www.ncbi.nlm.nih.gov/pubmed/27727003
http://dx.doi.org/10.1016/j.ebiom.2016.10.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264309/
https://www.ncbi.nlm.nih.gov/pubmed/27727003
http://dx.doi.org/10.1016/j.ebiom.2016.10.001

Ejemplares similares